IFNA1 and hepatocellular carcinoma: This result validates current guidelines and confirms and expands previous findings by Saraiya et al. [9], who showed that DAA-treated patients had a lower risk of HCC recurrence than untreated patients, while they did not compute any pooled analysis for DAA vs. IFN due to a paucity of data.